Used in the treatment of advanced solid tumors, this antibody functions as an immune checkpoint inhibitor by targeting the VISTA (V-domain Ig suppressor of T cell activation) protein. It helps restore anti-tumor immune responses by blocking the immunosuppressive signals in the tumor microenvironment. Currently investigated in clinical trials for cancers such as non-small cell lung cancer, melanoma, and other refractory solid tumors. Its application is primarily in immuno-oncology, where it may be used alone or in combination with other immunotherapies like anti-PD-1/PD-L1 antibodies to enhance therapeutic efficacy.